文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

美国急诊科住院尿路感染患者中产超广谱β-内酰胺酶肠杆菌的涌现

Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States.
PubMed 文献 · Ann Emerg Med · 2020-10-31
一句话结论美国11家急诊科住院尿路感染成人中,产ESBL肠杆菌占17.2%,且53.9%的ESBL感染在就诊12小时内未接受体外敏感抗生素治疗。

这项前瞻性多中心研究纳入2018-2019年美国11家大学附属医院急诊科收治的527例成人尿路感染患者,其中444例培养出肠杆菌科细菌。在435例完成确认试验的患者中,20.5%为产ESBL菌株;全体尿路感染患者中ESBL总患病率为17.2%。ESBL感染的危险因素包括医院、长期护理机构、90天内抗生素暴露及1年内氟喹诺酮或头孢曲松耐药菌株。头孢曲松是最常用的经验性抗生素,但53.9%的ESBL感染患者在就诊12小时内未接受体外敏感抗生素,合并脓毒症者中该比例为58.6%。

要点

  • 在11家美国急诊科住院尿路感染成人中,产ESBL肠杆菌总患病率为17.2%(95%CI 14.0%-20.7%),各中心范围4.6%-45.4%。
  • ESBL感染危险因素:医院、长期护理机构、90天内抗生素暴露、1年内氟喹诺酮或头孢曲松耐药菌株。
  • 肠杆菌科对其他抗生素耐药率:氟喹诺酮32.3%、庆大霉素13.7%、阿米卡星1.3%、美罗培南0.3%。
  • 53.9%的ESBL感染患者就诊12小时内未接受体外敏感抗生素,合并脓毒症者中58.6%未接受。
  • ESBL感染对比其他肠杆菌感染,接受体外敏感抗生素治疗的时间更长(17.3小时 vs 3.5小时)。

适用人群与场景

  • 2018-2019年美国11家地理分布不同的大学附属医院急诊科收治的成人尿路感染住院患者。

诊断标准与关键阈值

  • 尿路感染诊断基于培养确认的肠杆菌科感染。
  • ESBL确认试验:对分离株进行确认试验,阳性定义为产ESBL肠杆菌。

处置流程与药物剂量

  • 原文未提及具体抗生素剂量、给药途径、频次或疗程。
  • 头孢曲松是最常用的经验性抗生素。
  • 对ESBL感染,应使用体外敏感抗生素;原文报告53.9%的ESBL感染患者就诊12小时内未接受体外敏感抗生素。

红旗征与不能漏的情况

  • ESBL感染合并脓毒症:原文报告17例(58.6%)ESBL感染合并脓毒症患者在就诊12小时内未接受体外敏感抗生素。
  • ESBL感染患者接受体外敏感抗生素的时间更长(17.3小时 vs 3.5小时),提示需早期识别并调整经验性治疗。

研究设计与关键结果

  • 研究类型:前瞻性多中心观察性研究;样本量527例,来自11个中心;人群为急诊科住院尿路感染成人。
  • 主要结果:444例(84%)培养出肠杆菌科;435例完成确认试验者中89例(20.5%,95%CI 16.9%-24.5%)为产ESBL;全体尿路感染患者ESBL总患病率17.2%(95%CI 14.0%-20.7%)。
  • ESBL危险因素:医院、长期护理机构、90天内抗生素暴露、1年内氟喹诺酮或头孢曲松耐药菌株。
  • 其他耐药率:氟喹诺酮32.3%、庆大霉素13.7%、阿米卡星1.3%、美罗培南0.3%。
  • 治疗延迟:48例(53.9%)ESBL感染患者就诊12小时内未接受体外敏感抗生素,其中脓毒症者17例(58.6%);ESBL感染较其他肠杆菌感染接受体外敏感抗生素时间更长(17.3 vs 3.5小时)。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性研究。
  • 局限:原文未明确提及证据等级;各中心ESBL患病率差异大(4.6%-45.4%),可能影响外推性。

对床旁实践的改变

  • 在急诊科收治的尿路感染成人中,应考虑到产ESBL肠杆菌的可能,尤其存在医院、长期护理机构、90天内抗生素暴露或1年内氟喹诺酮/头孢曲松耐药菌株等危险因素时。
  • 头孢曲松作为常用经验性抗生素可能对ESBL感染无效,需尽早获取培养结果并调整至体外敏感抗生素,以减少治疗延迟。
  • 合并脓毒症的ESBL感染患者治疗延迟比例高,应优先识别并尽早给予体外敏感抗生素。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Enterobacteriaceae resistant to ceftriaxone, mediated through extended-spectrum β-lactamases (ESBLs), commonly cause urinary tract infections worldwide, but have been less prevalent in North America. Current US rates are unknown. We determine Enterobacteriaceae antimicrobial resistance rates among US emergency department (ED) patients hospitalized for urinary tract infection.

METHODS: We prospectively enrolled adults hospitalized for urinary tract infection from 11 geographically diverse university-affiliated hospital EDs during 2018 to 2019. Among participants with culture-confirmed infection, we evaluated prevalence of antimicrobial resistance, including that caused by ESBL-producing Enterobacteriaceae, resistance risk factors, and time to in vitro-active antibiotics.

RESULTS: Of 527 total participants, 444 (84%) had cultures that grew Enterobacteriaceae; 89 of 435 participants (20.5%; 95% confidence interval 16.9% to 24.5%; 4.6% to 45.4% by site) whose isolates had confirmatory testing had bacteria that were ESBL producing. The overall prevalence of ESBL-producing Enterobacteriaceae infection among all participants with urinary tract infection was 17.2% (95% confidence interval 14.0% to 20.7%). ESBL-producing Enterobacteriaceae infection risk factors were hospital, long-term care, antibiotic exposure within 90 days, and a fluoroquinolone- or ceftriaxone-resistant isolate within 1 year. Enterobacteriaceae resistance rates for other antimicrobials were fluoroquinolone 32.3%, gentamicin 13.7%, amikacin 1.3%, and meropenem 0.3%. Ceftriaxone was the most common empirical antibiotic. In vitro-active antibiotics were not administered within 12 hours of presentation to 48 participants (53.9%) with ESBL-producing Enterobacteriaceae infection, including 17 (58.6%) with sepsis. Compared with other Enterobacteriaceae infections, ESBL infections were associated with longer time to in vitro-active treatment (17.3 versus 3.5 hours).

CONCLUSION: Among adults hospitalized for urinary tract infection in many US locations, ESBL-producing Enterobacteriaceae have emerged as a common cause of infection that is often not initially treated with an in vitro-active antibiotic.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Talan DA, Takhar SS, Krishnadasan A, et al. Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States. Ann Emerg Med. 2020. PMID: 33131912. doi:10.1016/j.annemergmed.2020.08.022

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。